期刊
LANCET REGIONAL HEALTH-WESTERN PACIFIC
卷 8, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.lanwpc.2021.100098
关键词
Pertussis; Macrolide; Resistance
Whooping cough, caused by Bordetella pertussis, has seen a resurgence in mainland China with the emergence of macrolide-resistant strains. The primary treatment is macrolides, but alternative agents are urgently needed. International surveillance and prevention measures are crucial in preventing the spread of the resistant organism.
Whooping cough, or pertussis, is a highly communicable infectious disease caused by the bacterium Bordetella pertussis. Vaccination once reduced the incidence of the disease, but a global resurgence of the infection happened during the past two decades, likely due to the waning immunity of vaccination. Macrolides such as erythromycin and azithromycin are the drugs of primary choice for treatment. In this personal view, we call for attention to macrolide-resistant B. pertussis (MRBP), which has emerged and prevailed in mainland China for years and are exclusively mediated by mutations in the 23S rRNA gene. Whether the prevalence of MRBP in China results from overuse of azithromycin in clinical medicine remains unknown. The incidence of MRBP is low in other countries, but this could be a technical illusion since China employs culture as the mainstream diagnostic method whereas nucleic-acid amplification test being widely used in other countries fail to test antimicrobial susceptibility. Given the increasingly frequent global travel that facilitates microbial transmission worldwide, there is a pressing need to perform international surveillance on MRBP to prevent the potential circulation of the organism. Finding alternative agents that possess good activity against B. pertussis is also urgently required. (C) 2021 The Authors. Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据